Zepsyre has a path to market at last

After numerous twists and turns Pharmamar will no longer have to wait for next year’s binary outcome of the pivotal Atlantis trial before filing its small-cell lung cancer project Zepsyre. Instead, based on the just-revealed result of a call with the US FDA, filing for accelerated approval will take place in the fourth quarter.